A phase I, double-blind, placebo-controlled, single-dose, dose-escalation study of the safety, pharmacokinetics, and preliminary efficacy of XOMA 052 in subjects with type 2 diabetes mellitus.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Gevokizumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors XOMA
- 30 Sep 2009 Status changed from active, no longer recruiting to completed. Phase I trials of XOMA 052 are complete according to a XOMA media release.
- 14 Jul 2009 Interim results were reported in a Xoma media release; Xoma announced positive results from single and multiple dose subcutaneous arms of the trial; Placebo patients from both US and Sweden Phase I trials included.
- 09 Jun 2009 Results were presented at the American Diabetes Assocation 69th Annual Scientific Sessions.